Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis in a concentration-dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram-negative bacteria including extended-spectrum b-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and organisms with aminoglycoside-modifying enzymes. In a large phase III clinical trial, plazomicin was shown to be noninferior to meropenem in the treatment of complicated urinary tract infections (cUTIs) with respect to the coprimary efficacy end points of the microbiologically modified intent-to-treat composite cure rate at day 5 (plazomicin 88% [168/191 subjects] vs meropenem 91.4% [180/197]) and at the test-of-cure visit (plazomicin 81.7% [156/ 191] vs meropenem 70.1% [138/197]). In a small phase III clinical trial, plazomicin was shown to be effective in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. It was associated with a lower all-cause mortality or significant disease-related complication rate (23.5% [4/17]) compared with colistin (50% [10/20]). The most common adverse reactions associated with plazomicin are decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, and hypotension. As with other aminoglycosides, plazomicin may cause neuromuscular blockade, ototoxicity, and fetal harm in pregnant women. Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTIs in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4-7 days. Dosage reductions and therapeutic drug monitoring are warranted in patients with moderate or severe renal impairment. Plazomicin is not recommended in patients with severe renal impairment including those receiving renal replacement therapy. With the approval of plazomicin, clinicians now have an additional option for the treatment of adults with cUTIs, particularly those caused by multidrug-resistant gram-negative rods. KEY WORDS plazomicin, aminoglycosides, complicated urinary tract infections, bloodstream infections, multidrug-resistant Enterobacteriaceae.
Antimicrobial resistance remains one of the major health care threats across the world, particularly among gram-negative pathogens. 1, 2 Globally, there is an increased prevalence of resistant gram-negative pathogens such as multidrug-resistant Enterobacteriaceae including extended-spectrum b-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae (CRE). 3 The Centers for Disease Control and Prevention and World Health Organization both published reports that listed CRE-and ESBLassociated infections as leading public health threats. 4, 5 These reports further raised global awareness about the rise in incidence and difficulty in treating these multidrug-resistant infections. Significant health care burdens including increased lengths of stay, higher hospital costs, increased mortality, and risk of infection recurrences were associated with gram-negative bacterial infections. 6, 7 Currently available therapeutic agents that may be used to treat these pathogens have limitations in their spectra of activity and toxicity. Therefore, novel agents with enhanced spectra of activity are needed urgently.
Aminoglycosides traditionally were used for the treatment of gram-negative pathogens, but the spread of antimicrobial resistance and concerns regarding adverse effects have limited their use. 8, 9 To combat these issues, plazomicin (formerly known as ACHN-490), a next-generation semisynthetic aminoglycoside derived from sisomicin, was developed. 10 Sisomicin was isolated from Micromonospora inyoensis in 1970, and its chemical structure most closely resembles that of gentamicin. Although sisomicin had an increased spectrum of activity compared with other clinically available aminoglycosides at the time, it was susceptible to many aminoglycosidemodifying enzymes (AMEs), limiting its use. 10 Plazomicin (Zemdri; Achaogen, Inc., South San Francisco, CA) demonstrates in vitro activity against multidrug-resistant gram-negative pathogens and retains activity against AME-producing bacteria, in contrast to other available aminoglycosides. [10] [11] [12] Similar to other aminoglycosides, plazomicin exhibits concentration-dependent killing. 13 Due to its enhanced spectrum of activity, plazomicin was designated as a Qualified Infectious Disease Product by the U.S. Food and Drug Administration (FDA), receiving priority review and approval for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis. 14 In this review article, we discuss plazomicin's pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, dosing and administration, and potential role in therapy.
Literature Search
To gather relevant information, a literature search was performed using the PubMed, EBSCOhost Electronic Journal Service, and Google Scholar electronic databases (from January 1, 2009, to June 26, 2018) for articles published in the English language. Search terms used to identify in vitro and in vivo studies were plazomicin, ACHN-490, extended-spectrum b-lactamases, and CRE. The terms plazomicin + ACHN-490 identified 27 publications in the PubMed database; however, seven were excluded because five were review articles, one focused on pneumonic plague in a nonhuman primate model, and one was about chemical isolation and synthesis. The addition of extendedspectrum b-lactamases and carbapenem-resistant Enterobacteriaceae as PubMed search terms did not result in additional journal articles. The terms plazomicin and ACHN-490 were used together and individually and did not yield any journal articles for inclusion in either the Google Scholar or EBSCOhost Electronic Journal Service databases. Clinical trials with plazomicin were identified from Clinicaltrials.gov. Two FDA review documents were examined for vital information to summarize in this review article. Information about plazomicin was also obtained from research presented at international conferences such as the Interscience Conference on Antimicrobial Agents and Chemotherapy, IDWeek, the American Society for Microbiology Microbe, and the European Congress of Clinical Microbiology and Infectious Diseases. Twenty-nine research posters and abstracts were used for this review that are easily accessible online in conference proceedings and publicly available from Achoagen's Web site (achaogen.com/scientific-publications-plazomicin).
Chemistry and Pharmacology
Plazomicin (also known as ACHN-490) is a novel aminoglycoside, synthetically derived from sisomicin, an older, naturally occurring aminoglycoside ( Figure 1) . 15 Similar to other aminoglycosides, plazomicin exerts its effect by binding to the 30S portion of the bacterial ribosome, thereby inhibiting bacterial protein synthesis in a bactericidal manner. 16 Although plazomicin bears some structural similarities to sisomicin, it also possesses some novelty in its 78 PHARMACOTHERAPY Volume 39, Number 1, 2019 chemical structure. 15, 17, 18 Like sisomicin, plazomicin lacks a 3 0 -or 4 0 -hydroxyl group that affords protection against inactivation by enzymes that inactivate amikacin, the broadest spectrum aminoglycoside available. However, plazomicin is distinguished from sisomicin by the addition of a hydroxyl-aminobutyric acid group at position 1 and hydroxyethyl group at the 6 0 position of sisomicin, enhancing its spectrum of activity against organisms possessing AMEs.
15, 16

Microbiological Activity
Plazomicin is a broad-spectrum antibiotic with in vitro activity against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus sp including methicillin-resistant S. aureus (MRSA). In addition, plazomicin has demonstrated activity against ESBL-producing Enterobacteriaceae, CRE, and pathogens exhibiting AME genes. As with other aminoglycosides, plazomicin exhibits poor activity against gram-negative and grampositive anaerobes. Although most data available are for Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria, in vitro data indicated that plazomicin had activity against some New Delhi metallo-b-lactamase (NDM)-producing organisms (80-92% susceptible), particularly when these isolates did not harbor the 16S rRNA methylase gene. [19] [20] [21] Plazomicin also has reduced or no activity against Enterococcus sp, Streptococcus sp, Acinetobacter sp, and Stenotrophomonas sp.
14 The drug has variable activity and higher minimum inhibitory concentrations (MICs) for 50% and 90% of isolates, respectively (MIC 50/90 ), to non-lactose-fermenting aerobic gram-negative pathogens including Morganella morganii, Proteus sp, and Pseudomonas sp. 10, 12, [22] [23] [24] [25] [26] [27] [28] Table 1 summarizes the in vitro susceptibility of various organisms to plazomicin. 10, 19, 20, 22-24, 26, 29-38 Plazomicin's in vitro activity against Yersinia pestis and Francisella tularensis was also demonstrated. [25] [26] [27] In comparison with gentamicin (MIC 90 0.5 µg/ml), plazomicin exhibited MIC 50/90 0.5/1 µg/ml against both Y. pestis (28 subjects) and F. tularensis (30 subjects) isolates. 25 The authors concluded that plazomicin demonstrated activity against gentamicin-susceptible Y. pestis and F. tularensis.
One study 22 evaluated the activity of plazomicin and comparator agents (e.g., amikacin, tobramycin, and gentamicin) against a total of 6417 clinical isolates of Enterobacteriaceae, gram-positive pathogens, P. aeruginosa, and Acinetobacter sp collected from 90 hospitals worldwide. At 4 µg/ml or less, plazomicin inhibited 94.8% of gentamicin-resistant, 94.9% of tobramycin-resistant, and 41.1% of amikacinresistant Enterobacteriaceae isolates. Of the 204 CRE isolates examined, plazomicin inhibited 90.2% at 4 µg/ml or less and exhibited an MIC 50/90 of 0.25/4 µg/ml. Amikacin, gentamicin, and tobramycin inhibited 70.1%, 54.4%, and 15.2%, respectively, of these CRE isolates. Plazomicin activity was studied against Enterobacteriaceae isolates exhibiting aminoglycoside and b-lactam resistance mechanisms. 23 Nearly 95% of ESBLproducing isolates were inhibited with plazomicin at 4 mg/L or less (MIC 50/90 0.25/0.5 mg/ L); CTX-M was the most common ESBL gene detected. Nearly 79% of CRE isolates were inhibited with plazomicin at 2 mg/L or less or 4 mg/L or less (MIC 50/90 0.25/more than 128 mg/L); KPC was the most common carbapenemase gene detected. Nearly 94% of the AME-producing Another study 24 demonstrated that plazomicin exhibited the most potent in vitro activity by inhibiting 98% of CRE isolates (MIC 50/90 of 0.5/1 mg/L). One report 12 tested the activity of plazomicin against 95 colistinresistant Enterobacteriaceae isolates. Plazomicin inhibited 89.5% and 93.7% of these colistinresistant isolates at 2 mg/L or less and 4 mg/L or less, respectively. Twenty-one of the isolates (E. coli [17] and Salmonella enterica [4] ) had the acquired mcr-1 plasmid. Plazomicin (MIC 50/90 1/2 mg/L) inhibited 100% of the mcr-1 gene isolates at 2 mg/L or less and exhibited the most potent in vitro activity against colistinresistant Enterobacteriaceae, with an MIC 90 of 4 mg/L. Includes Finegoldia magna (n=3), Propionibacterium acnes (n=2), and P. avidum (n=1). Includes Clostridium innocuum (n=3), C. perfringens (n=3), C. ramosum (n=3), and C. difficile (n=3).
Resistance Mechanisms
Bacteria use three currently known mechanisms of resistance against aminoglycosides. 15, 16 Ribosomal modification allows for structural modification of the target site within the ribosome, thus decreasing the affinity of the aminoglycoside to the site of action. 15 Alteration of aminoglycoside uptake and efflux is another mechanism of resistance that results in a decreased drug concentration at the site of action. 15 By far the most commonly encountered mechanism of resistance is via AMEs. Like ribosomal modification, AMEs reduce the affinity of the aminoglycoside to the target site within the ribosome, but unlike ribosomal modification, AMEs do so by chemically modifying an aminoglycoside functional group. It is the new additions at position 1 and 6 0 on plazomicin that allow for protection against nearly all AMEs, with an exception of aminoglycoside N-acetyltransferase (2 0 )-I, which is found chromosomally in Providencia stuartii. 16 Fortunately, to our knowledge, there is no evidence of transfer of this intrinsic resistance mechanism from P. stuartii to other Enterobacteriaceae. 16 The unique chemistry of plazomicin, however, does not provide protection against the remaining mechanisms of resistance; even early studies noted an increase in MIC when plazomicin was used against bacterial isolates with mutations conferring changes in membrane permeability or increased expression of efflux pumps, or in the presence of ribosomal methyltransferase. 10, 17, 39 For this reason, plazomicin is unlikely to offer additional activity beyond that of other aminoglycosides when considering either Pseudomonas aeruginosa or Acinetobacter sp; although AMEs are seen in these organisms, changes in outer membrane permeability and upregulation of efflux pumps also commonly accompany AMEs in these organisms. 16 Of the existing aminoglycoside resistance mechanisms, ribosomal methylation is of particular concern because it confers a broad resistance profile that currently renders all aminoglycosides clinically in use inactive. 40 Genes encoding ribosomal methylases were found on transferrable plasmids and transposons, thus raising the concern for easy transfer among bacterial isolates. 15, 41, 42 Also concerning is the fact that these ribosomal methyltransferases are often found coexisting with other resistance mechanisms and were reported to be found in conjunction with ESBLs; metallo-b-lactamases (MBLs), such as the NDM and SPM-1 MBL; and OXA-type carbapenemases. 43 As a result of these coexisting resistance mechanisms, plazomicin was found to be inactive against isolates carrying NDM because ribosomal methyltransferases commonly are found with NDM. 39 Although ribosomal methyltransferases are an uncommon mechanism of resistance relative to AMEs, they are responsible for an important gap in plazomicin activity. 44 
Pharmacokinetics
The pharmacokinetics of plazomicin were examined by several phase I clinical trials. At steady state, plazomicin 15 mg/kg administered as a 10-minute infusion every 24 hours achieved a mean AE SD area under the concentration-time curve from time zero to 24 hours (AUC 0-24 ) of 239 AE 45 hour•mg/L, maximum plasma drug concentration (C max ) of 113 AE 17 mg/L, elimination half-life (t 1/2 ) of 3 AE 0.3 hours, steady-state volume of distribution (V ss ) of 0.24 AE 0.04 L/kg, and systemic clearance (Cl) of 1.1 AE 0.1 ml/minute/kg (Table 2) . 45 Plazomicin is predominantly unmetabolized in the body and primarily eliminated as the parent drug through glomerular filtration. Renal clearance (CLr) was estimated to be 4.19 L/hour that accounts for 86.9% of plazomicin total clearance. 46 The mean AE SD of plazomicin plasma protein binding is low at 16% AE 5%. 45 The penetration of plazomicin into pulmonary epithelial lining fluid in healthy human subjects with noninflamed lungs was 12.8% (calculated as the ratio of epithelial lining fluid to plasma area under the curve [AUC]). 47 This is similar to amikacin's lung penetration ability that was observed in healthy human subjects as well. 48 One group 49 compared pharmacokinetic parameters for standard-dose (15 mg/kg) and supratherapeutic dose (20 mg/kg) plazomicin administered as a single 30-minute infusion. Plazomicin C max and AUC 0-24 both increased with 20-mg/kg dosing; however, no significant differences were found in mean terminal-phase t 1/2 , total clearance (Cl T ), and V ss between the 15-and 20-mg/kg dosing cohorts. After dosing plazomicin at 15 mg/kg administered as a 30-minute infusion, the pharmacokinetic parameters (AUC 0-24 , t 1/2 , Cl T , and V ss ) observed were similar to the parameters observed after administration of a 10-minute infusion that were seen in another study. 45 However, mean C max observed after the 30-minute infusion was reduced by 47% compared with the previously reported mean C max after a 10-minute infusion. 45 Plazomicin was also examined in individuals with renal impairment. One report 50 studied subjects with normal renal function (creatinine clearance [Cl cr ] of 90 ml/min or higher) and mild (Cl cr 60-89 ml/min), moderate (Cl cr 30-59 ml/min), and severe (Cl cr 15-29 ml/min) renal dysfunction after administration of a 7.5-mg/kg single dose of plazomicin. Patients receiving renal replacement modalities (i.e., peritoneal dialysis, hemodialysis, and continuous renal replacement therapy) were not included in this study. Individuals with mild impairment had similar pharmacokinetic parameters to those with normal renal function. However, subjects with moderate and severe renal impairment had a significantly lower total CL (0.48-fold and 0.20-fold, respectively) and higher drug exposure (based on AUC from time zero extrapolated to infinity; 1.98-fold and 4.42-fold, respectively) than individuals in the normal renal function cohort. Based on these observations, dosage adjustments for patients with moderate and severe renal dysfunction were determined to be necessary to achieve a target AUC.
Pharmacodynamics
Similar to other aminoglycosides, plazomicin is rapidly bactericidal in vitro with concentration-dependent killing. 51 In time-kill assays, plazomicin exhibited bactericidal activity, defined as a greater than or equal to a 3-log 10 colonyforming unit (CFU)/ml decrease relative to initial count, against all eight pathogenic isolates (including E. coli, E. aerogenes, K. pneumoniae, and S. aureus) tested. 52 Of note, seven of the eight isolates tested had a single AME phenotype. Plazomicin's bactericidal effect was seen between 1 and 4 hours for all strains. In another time-kill study, plazomicin demonstrated bactericidal activity against 7 of 9 E. coli and all 15 K. pneumoniae isolates. 10 Most of the K. pneumoniae isolates were multidrug resistant and exhibited AMEs. Based on these two studies, the bactericidal activity for plazomicin occurs in most isolates at concentrations 4 times the MIC. 10, 52 Dose-response efficacy of plazomicin was evaluated in a neutropenic mouse thigh model against CRE. 53 The nine CRE isolates tested had plazomicin MICs ranging from 0.125-1 µg/ml. Plazomicin displayed a clear dose-response relationship for all isolates tested. Plazomicin achieved net bacterial stasis with a median dose of 5.4 mg/kg/day and a 1-log CFU reduction with a median dose of 20.5 mg/kg/day. The human-equivalent dose (~4.3 mg/kg/day) of the highest plazomicin dose required for a 1-log CFU reduction (36.7 mg/kg/day) is more than 3-fold lower than the current human dose for plazomicin (15 mg/kg/day).
In vitro synergy time-kill studies were also performed for plazomicin in combination with various gram-positive and gram-negative active antibiotics. In one of the time-kill assays, plazomicin synergy was examined against 25 P. aeruginosa isolates with different resistance phenotypes including AMEs. 54 At 24 hours, synergy was observed with subinhibitory concentrations of plazomicin in combination with cefepime (80% of isolates), doripenem (80% of isolates), imipenem (68% of isolates), and Data are mean AE SD values. Ae = fraction of drug excreted in the urine over the dosing interval; AUC 0-24 = area under the concentration-time curve from time zero to 24 hrs; AUC 0-∞ = area under the concentration-time curve from time zero extrapolated to infinity; CL, w = systemic clearance, adjusted for body weight; CLr, w = renal clearance, adjusted for body weight; C max = maximum plasma drug concentration; C min = minimum plasma drug concentration; ND = not determined; t 1/2 = elimination half-life; V ss , w = steady-state volume of distribution, adjusted for body weight. The observed PAE lasted up to 0.8 hour, with most strains having a PAE of at least 0.5 hour, and it was found to be similar to the PAE observed for other aminoglycosides. 55 The PAE of plazomicin was found to increase with increasing drug concentrations and was able to last for at least 2 hours once drug concentrations exceeded 8 times the MIC. 56 One group 57 studied plazomicin in combination with daptomycin, linezolid, and ceftobiprole against 47 MRSA isolates. These isolates included heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus, and hospital-and community-acquired MRSA strains. Synergy was observed with subinhibitory concentrations of plazomicin in combination with daptomycin (91% of isolates), linezolid (13% of isolates), and ceftobiprole (36% of isolates). In both studies, plazomicin antagonism was only observed in combination with linezolid in 4% of isolates. 54, 57 For activity against gram-negative pathogens, studies demonstrated that the pharmacokinetic/ pharmacodynamic parameter best predictive of efficacy is AUC 0-24 :MIC. 27, 58, 59 When considering target drug concentrations for clinical success, concentrations resulting in bacterial stasis were deemed an appropriate target for treatment of cUTI because plazomicin concentrates well at the site of infection, and cUTI was considered to be a relatively non-life-threatening condition. 27 Based on a neutropenic mouse thigh model, an AUC 0-24 :MIC target of 18 was shown to be associated with bacterial stasis. 27 Monte Carlo simulations using AUC 0-24 :MIC ratio targets found in animal studies to be associated with bacterial stasis predict more than 90% probability of target attainment (PTA) for organisms with MIC values up to 4 mg/L. 59 In addition, in trials evaluating cUTI, utilization of the stasis target best predicted good clinical outcomes. 27 A 15-mg/kg/ day dose of plazomicin is expected to adequately achieve the necessary pharmacokinetic/pharmacodynamic goals and thus is expected to adequately treat cUTI caused by an organism with an MIC up to 4 mg/ml. Based on available modeling data and clinical data, the manufacturer has recommended that monitoring of trough levels in patients being treated for cUTI was sufficient for therapeutic drug monitoring (TDM). 27 A trough higher than 2 µg/ml was found to be associated with an increased risk of nephrotoxicity; thus an initial goal trough lower than 2 µg/ml had been proposed. However, an FDA analysis of data revealed that a plazomicin concentration of 3 µg/ml was the critical cutoff for nephrotoxicity; thus the plazomicin package insert recommends a goal trough level lower than 3 µg/ml.
14 In instances of elevated trough levels, rather than a dose decrease, extension of the dosing interval and continued monitoring is proposed. 27 For treatment of a bloodstream infection (BSI), both stasis and 1-log 10 kill targets were considered; 1-log 10 kill was deemed to be a more appropriate target and was thus used to examine pharmacokinetic/pharmacodynamic relationships in patients receiving plazomicin for treatment of a BSI. 27 A neutropenic murine thigh infection model demonstrated that an AUC 0-24 :MIC of 73 was associated with a 1-log 10 kill. 27 Monte Carlo simulations applying this AUC 0-24 :MIC value found a 90% or higher PTA for organisms with an MIC of 2 µg/ml or lower. 27 Due to the expected severity of illness associated with a BSI, a greater variation of pharmacokinetic parameters is expected; therefore, the manufacturer-recommended TDM when plazomicin is used to treat a BSI differs from recommendations when the drug is used for treatment of cUTI. 27 Based on available data, the manufacturer has recommended performing TDM by measuring two levels and performing calculations to adjust for a target AUC 0-24 of 210-315 µg•hour/ml when using plazomicin for BSI treatment. 27 These upper and lower bounds were chosen by the manufacturer based on the fact that they approximate the 10th and 90th percentile of AUC 0-24 found in clinical trials. 27 However, the FDA has raised concerns with the proposed range; an analysis of the relationship between the upper bound of AUC 0-24 and corresponding trough concentrations suggests that the proposed upper bound may be associated with an increased risk of nephrotoxicity. 28 The proposed lower bound is also based on an AUC 0-24 :MIC target for bacterial stasis; FDA analysis of the proposed lower bound thus also suggests that a different AUC 0-24 range may be more appropriate. Further studies will likely be necessary to fully elucidate optimal TDM goals for plazomicin, but the proposed goals are summarized in Table 3 .
Clinical Efficacy
The efficacy and safety of plazomicin were evaluated in a single phase II study and phase III study for cUTIs in adult patients. 27, 60, 61 Plazomicin was also evaluated in one phase III study for serious infections caused by CRE in adult patients. 62, 63 Table 4 summarizes these clinical trials. [60] [61] [62] Complicated Urinary Tract Infections
The efficacy and safety of plazomicin for the treatment of cUTIs including acute pyelonephritis (AP) was evaluated in one phase II clinical trial. 60 This multicenter, multinational, doubleblind, randomized phase II study compared intravenous (IV) plazomicin 10 and 15 mg/kg every 24 hours for 5 days with IV levofloxacin 750 mg every 24 hours for 5 days in 145 adult patients with cUTIs or AP. 27 The coprimary end points were rates of microbiologic eradication rates at the test-of-cure (TOC) visit (5-12 days after the last treatment dose) in the modified intent-to-treat (mITT) cohort and in the microbiologically evaluable (ME) cohort. Clinical outcomes were assessed as a secondary end point. Baseline characteristics in the mITT population were not significantly different between treatment arms; enrolled patients were recruited from study sites in the United States, India, Colombia, and Chile. Patients had a mean age of 42.4 years, most were female (83.7%), and 48.9% had a diagnosis of AP. The most commonly isolated organisms in the mITT population were Enterobacteriaceae, of which 16.2% were classified as multidrug resistant. The microbiologic eradication rates at TOC visit in the mITT population were comparable for plazomicin 10 mg/kg (50% [6/12] [17/ 21] ). In the ME population, eradication rates were similar for all treatment groups according to primary diagnosis (cUTI or AP) and baseline pathogen. Observed clinical cure rates in the mITT group were 66.7%, 70.6%, and 65.5% for the plazomicin 10-mg/kg group, plazomicin 15-mg/kg group, and levofloxacin group, respectively. In the ME group, cure rates were 57.1%, 80%, and 76.2% in the plazomicin 10-mg/kg group, plazomicin 15-mg/kg group, and levofloxacin group, respectively. Cure rates associated with plazomicin in the mITT population with an antibiotic-resistant Enterobacteriaceae ranged from 75-100% in the group receiving plazomicin 10 mg/kg, 66.7-100% in the group receiving plazomicin 15 mg/kg, and 66.7-100% in the group receiving levofloxacin. Although limited by its small sample size and the fact that many patients had an indeterminate outcome in the mITT population for each treatment group, the study was able to include patients with resistant pathogens and was thus able to demonstrate successfully that there is merit in continuing to investigate plazomicin utility in the treatment of cUTI and AP.
A randomized, multicenter, multinational, double-blind, noninferiority phase III (EPIC) study evaluated the efficacy and safety of plazomicin 15 mg/kg IV every 24 hours compared with meropenem 1 g IV every 8 hours for at least 4 days followed by an optional conversion from IV to levofloxacin 500 mg oral therapy in the treatment of 609 adults with cUTIs including AP for 7-10 days. 60 It is unclear why the dose for levofloxacin deviated from the prior study. The coprimary end points were composite ME and clinical cure rate in the microbiological mMITT population at day 5 and TOC visits. The term coprimary for this study meant that a 15% noninferiority (NI) margin (with 95% confidence interval [CI]) had to be shown for the primary end point at both day 5 and TOC. The specified NI margin of 15% is wider than the 10% margin recommended in the FDA guidance document on cUTI and was agreed to by the FDA to support plazomicin's limited use for patients with cUTI/AP who have limited or no other treatment options. Overall, the mITT demographics were comparable between the two treatment groups, and most patients were of European descent. The types of infections varied slightly. In the clinically evaluable patients, the mITT demographics [26/ 197] ). 61 Members of the Enterobacteriaceae family were the most commonly isolated uropathogens, with E. coli the most common in both treatment groups. Nearly 28% of the mMITT population had an ESBL-producing Enterobacteriaceae, with predominantly the CTX-M enzyme type. Nearly 27% of these isolates were nonsusceptible to currently available aminoglycosides, with aac(6 0 )-Ib and aac(3)-IIa as the most common AME genes detected. Plazomicin was effective in the treatment of patients with cUTI and demonstrated noninferiority to meropenem with respect to the coprimary efficacy end points of the mMITT composite cure rate at day 5 (plazomicin 88% [168/191] 27, 28 Limitations to this study include the use of composite end points and adjustment of the noninferiority margin. Composite end points are commonly used in clinical trials, principally to increase statistical power and thereby avoid a type II error, in which a difference between treatment arms is missed because of an insufficient number of events. 64 Investigators were able to gain FDA approval for a wider noninferiority margin from 10-15% that calculates a smaller sample size and thus improves chances for demonstrating noninferiority. This can erroneously result in demonstrating noninferiority when plazomicin was actually inferior.
Serious Infections Caused by CarbapenemResistant Enterobacteriaceae
The efficacy of plazomicin was further evaluated in patients with an infection caused by CRE. 27, 62 The design was an open-label, multicenter, phase III (CARE) study composed of two cohorts: a randomized (1:1), comparator-controlled cohort (cohort 1) and a single-arm cohort (cohort 2). Cohort 1 compared the efficacy and safety of plazomicin with colistin, each in combination with a second antibiotic (meropenem or tigecycline) in the treatment of patients with BSI or hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia (HABP/VABP). The primary outcome was all-cause mortality (ACM) at day 28 or significant disease-related complications (SDRCs) in cohort 1. Significant disease-related complications were defined as new or worsening acute respiratory distress syndrome, new lung abscess or empyema, or new-onset septic shock within 7 days (BSI or HABP/VABP); persistence of bacteremia for 5 days or longer (BSI only); or newonset bacteremia (HABP/VABP only). In the clinically evaluable patients, 82.4% (14/17) had BSI and 17.6% (3/17) had HABP/VABP in the plazomicin arm, and 75% (15/20) had BSI and 25% (5/20) had HABP/VABP in the colistin arm. The most common CRE-producing organism isolated was K. pneumoniae in both arms. Plazomicin was effective at treating patients with a CRE infection and had a lower rate of ACM or SDRC (23.5% [4/17] ) compared with colistin (50% [10/20] 28 Among patients who experienced SDRC and survived at day 28, one had worsening septic shock, and one had persistent CRE bacteremia for 5 days or longer in the plazomicin-treated group; two patients had persistent CRE bacteremia for 5 days or longer in the colistin-treated group. 27 In cohort 2, access to plazomicin therapy was permitted for patients with a BSI, HABP/VABP, cUTI, or AP who were ineligible for inclusion into cohort 1. 27, 62 At the time of enrollment of this second cohort, patients with a BSI or HABP/VABP were permitted at least one adjunctive antibiotic with activity against Enterobacteriaceae selected by the investigator to be added to plazomicin. Patients with cUTI and AP did not receive adjunctive antibiotic therapy. In the clinically evaluable patients, 4 had cUTI/AP, 9 had HABP/VABP, and 14 had BSI. 27 The investigators reported results for plazomicin in the subgroup with BSI only; the rate of ACM at day 28 or SDRCs was 35.7% (5/14), with most events driven by SDRCs (28.6% [4/14] ). 27, 63 The higher rate of SDRCs could be associated with three patients who had persistent CRE bacteremia associated with IV catheters that subsequently resolved. 27 This study was limited due to its small sample size, data could only be described using descriptive statistics, and the restrictive enrollment criteria to recruit patients with these challenging infections caused by multidrug-resistant organisms.
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The study permitted enrollment of patients with negative CRE cultures within 24 hours of randomization, up to 72 hours of an alternative antimicrobial therapy, and adjunctive therapy with meropenem or tigecycline for the entire treatment duration. 61 These criteria can introduce many confounders, making the true effect of plazomicin unknown. This study also did not provide sufficient evidence for FDA approval for treatment of BSI and HABP/VABP with plazomicin.
Investigators then conducted a subgroup analysis on all patients enrolled in both cohorts of the study who had a confirmed CRE-associated BSI (29 in cohort 1; 14 in cohort 2). 63 Patients treated with plazomicin had a lower rate of ACM or SDRC (14.3% [2/14] vs 53.3% [8/15] , À39, 90% CI À65.5 to 9.4) and ACM alone (7.1% [1/14] vs 40% [6/15] À32.9, 90% CI À60.1 to 4.0) compared with those with a colistin-based treatment (Table 4) . Plazomicin treatment was associated with an 86% reduction in the rate of death over 28 days and a 63% reduction in rate of death over 60 days compared with colistin treatment, with the separation between treatment arms evident by day 14 and sustained through day 60 (hazard ratio 0.37, 90% CI 0.15-0.91).
Safety and Tolerability
Notorious adverse effects of aminoglycosides are nephrotoxicity, ototoxicity, and, on rare occasions, neuromuscular blockade. Safety and tolerability data from several clinical trials so far showed that plazomicin, when given for a short duration of time, was not plagued with these drug class adverse effects to the same extent as older aminoglycosides.
14, 27 Two randomized double-blind placebo-controlled phase I studies investigated the safety and tolerability of plazomicin in healthy subjects. 45 Study 1 used a parallel-group design with escalating single and multiple doses. Subjects in the plazomicin arm received a single dose of 1 mg/kg followed by ascending single-and multiple-dose cohorts of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days, respectively. The most frequently observed treatment-emergent adverse effects (TEAEs) were headache ( 6 [17%] ), again without lasting sequelae. Subjects underwent vestibular and cochlear function testing for up to 6 months after the final study dose, and these studies revealed no otic abnormalities. Most subjects maintained normal renal function throughout these studies. Three patients in study 1 had mild, transient elevations of serum creatinine (S cr ) concentration, and two subjects in study 2 had a transient decrease in estimated Cl cr . However, renal function returned to normal for all subjects during the treatment period.
In an open-label multicenter phase I study, plazomicin safety and tolerability was assessed in 24 subjects with normal and impaired renal function. 27, 50 Subjects received a single lower plazomicin dose of 7.5 mg/kg administered over 30 minutes to mitigate the risk of nephrotoxicity and ototoxicity because exposure was expected to increase in those with renal impairment. At baseline, calculated mean estimated Cl cr was 115.3 ml/minute in subjects with normal renal function and 75.9, 49.5, and 21.2 ml/minute in subjects with mild, moderate, or severe renal dysfunction, respectively. Investigators identified 12.5% (3/24) of subjects with a treatment-associated adverse event, and all were deemed unrelated to plazomicin. The reported TEAEs were mild upper respiratory tract infection (1/24 [4.2%]), mild headache (1/24 [4.2%]), and moderate epicondylitis (1/24 [0.04%]). No serious adverse effects were reported despite a higher average plazomicin concentration in subjects with renal impairment. AUC 0-∞ values were similar among subjects with mild renal dysfunction and subjects with normal renal function (p=0.9422). 50 AUC 0-∞ values were significantly higher for subjects with moderate renal dysfunction (1.98-fold, p=0.0023) and severe renal dysfunction (4.42-fold, p=0.0003) compared with subjects with normal renal function. 50 Another phase I study examined the safety and tolerability of plazomicin 15 mg/kg IV once/day for up to 5 days in healthy subjects. 47 The most frequently observed TEAEs were dizziness ( QTc-interval prolongation was assessed during a randomized, double-blind, placebo-and positive-controlled, single-center phase I study in healthy adults. 65 Overall, the single doses of plazomicin were well tolerated and not associated with clinically significant QTc-interval prolongation. The most common adverse effects were hypoesthesia, headache, nausea, and dizziness. Other adverse effects reported were ear discomfort, tinnitus, vomiting, dizziness, somnolence, anxiety, and cough. All symptoms resolved by the end of the study.
In the previously described phase II study, the most frequently reported adverse effects in the plazomicin arms were headache, nausea, vomiting, diarrhea, and dizziness, and most were deemed by the investigators to be mild to moderate in severity. 60 A 23-year-old woman experienced a spontaneous abortion on day 103 in the 15-mg/kg plazomicin arm, and it was considered unrelated to the study drug. Four patients who received plazomicin 15 mg/kg had adverse effects that required discontinuation of therapy. One patient experienced severe hypotension with moderate dizziness on day 3 of therapy on receipt of the 30-minute plazomicin and 90-minute placebo infusion. The patient's blood pressure normalized 2 hours and 15 minutes after the onset of the hypotensive episode. These effects were considered related to the study drug and resolved without further complications. On day 3 of therapy, a 55-year-old woman discontinued plazomicin secondary to worsening of preexisting diabetes mellitus that was deemed unrelated to plazomicin and mild azotemia deemed related to plazomicin. The patient's S cr concentration increased from a baseline of 1.6 to 2.1 mg/dl, but it returned nearly to baseline at a follow-up visit and was documented as 1.8 mg/ dl. Two patients, one with moderate dizziness and one with mild transient vertigo, discontinued plazomicin after two doses. These adverse effects were both considered related to plazomicin and resolved without further complications.
In the phase II study, two patients who received plazomicin at 15 mg/kg experienced renal adverse effects. 60 One patient had mild azotemia (as previously described), and the other patient experienced mild acute renal insufficiency. The second patient's S cr concentration increased from 0.9 to 1.6 mg/dl at the TOC visit and returned nearly to baseline level at a followup visit and was documented as 1.1 mg/dl. Most patients had stable S cr concentration values throughout the duration of the study. Five plazomicin-treated patients had a 0.5-mg/dl or more increase in S cr concentration from baseline during the study period. The S cr concentration returned nearly to baseline during follow-up in all but one plazomicin-treated patient. The patient with continued S cr elevation began with a baseline value of 1.2 mg/dl, and by the end of therapy on day 5, the S cr concentration was 2.0 mg/dl. The patient's S cr concentration remained above baseline at 1.8 mg/dl at a follow-up visit. Two plazomicin-treated patients experienced adverse effects associated with vestibular and cochlear function. As described earlier, one patient experienced mild transient vertigo after receiving the second dose of plazomicin. A second patient, a 47-year-old woman with normal audiogram results, experienced mild unilateral tinnitus 14 days after the end of therapy. Repeat audiograms showed normal hearing levels; however, mild unilateral tinnitus persisted at 3 months. None of the plazomicintreated patients experienced hearing loss.
In the previously described phase III study, patients were randomized to receive plazomicin or meropenem for cUTIs or AP and were monitored for 34 days for development of adverse effects. 61 Plazomicin was overall well tolerated. The most commonly reported TEAEs were diarrhea (2.3%), hypertension (2.3%), headache (1.3%), nausea (1.3%), and vomiting (1.3%), and all were mild to moderate in severity. Plazomicin's impact on renal function was comparable with meropenem; 7% (21/300) experienced a 0.5-mg/dl or higher increase in S cr concentration at any time during the study period, and 3.7% (11/300) had a 0.5-mg/dl or higher increase while receiving IV therapy. Most of the plazomicin-treated patients experienced a full recovery by the end of therapy (6/11 [55%] ) and last follow-up visit (9/11 [82%] ). Another phase III study reported a satisfactory safety profile for plazomicin-treated patients compared with colistin when used as part of a combination therapy for a CRE infection. 27, 62 Nearly all of these severely ill plazomicin-treated patients experienced at least one TEAE (42/48 [88%] ). TEAEs related to renal function and sepsis were more common in colistin-treated patients than in plazomicin-treated patients (52.4% [11/21] To our knowledge, no data are available regarding the use of plazomicin in pregnant or breastfeeding women. A low concentration of plazomicin was detected in rat milk.
14 Aminoglycosides are known to cross the placenta, leading to concerns for fetal nephrotoxicity and ototoxicity. Case reports were published describing hearing loss and eighth cranial nerve damage in children whose mothers received streptomycin and kanamycin therapy during pregnancy. 66, 67 Because of the available historical data, patients and clinicians should be informed that fetal harm could arise with the use of plazomicin during pregnancy.
Clostridium difficile-associated diarrhea has been reported for nearly all antibacterial drugs. Patients should be monitored and evaluated accordingly if diarrhea occurs while receiving plazomicin. To our knowledge, no cases of C. difficile-associated diarrhea have been reported with plazomicin.
Drug Interactions
To date, pharmacokinetic drug-drug interaction studies have indicated that plazomicin is an unlikely substrate, inhibitor, or inducer of any of the major drug-metabolizing enzymes, or inhibitor of the major hepatic or renal drug transporters, with the exception of multidrug and toxin extrusion 2-K (MATE2-K). 14, 27 In vitro studies found that high concentrations of plazomicin selectively inhibited the MATE1 and MATE2-K drug transporters. 14, 27 As a result, a phase I study was conducted to investigate concomitant plazomicin and metformin therapy. 27 Metformin is a commonly used antidiabetic agent and known substrate of MATE and organic cation transporter (OCT) 2 drug transporters. 68 This study revealed that plazomicin 15 mg/kg had no effects on the plasma pharmacokinetics and rate and extent of excretion of metformin. Therefore, plazomicin is an unlikely in vivo inhibitor of MATE or OCT2 transporters. In vitro data indicated that plazomicin is not a substrate of P-glycoprotein or breast cancer resistance protein transporters. 14, 27, 28 Because nearly all of plazomicin is excreted as an unchanged drug in the urine, it is unlikely to be a culprit of major drug-drug interactions.
Dosage, Monitoring, Availability, Administration, Storage, and Stability
The recommended dosage of plazomicin is 15 mg/kg every 24 hours for adult patients with normal renal function. Therapeutic drug monitoring to maintain plasma trough concentrations below 3 µg/ml is recommended in patients with a Cl cr lower than 90 ml/minute, and dosage adjustment may be needed accordingly. Table 5 summarizes dosing recommendations, monitoring, and adjustments based on renal function. The approved duration of therapy of plazomicin for cUTI is 4-7 days and should be guided by the severity of infection and the patient's clinical status. Creatinine clearance estimated by the Cockcroft-Gault equation using total body weight. For patients whose total body weight is greater than ideal body weight by 25%, use ideal body weight. b Calculate dose using total body weight. For patients whose total body weight is greater than ideal body weight by 25% or more, use adjusted body weight. Adjusted body weight = ideal body weight + 0.4 9 (total body weight À ideal body weight). Plazomicin is supplied in 10-ml single-dose vials containing plazomicin sulfate equivalent to 500 mg plazomicin free base in water for injection and sodium hydroxide to achieve a pH of 6.5. Vials should be stored or refrigerated at 2-8°C.
14
14 Each vial of plazomicin should be diluted in 0.9% sodium chloride for injection or lactated Ringer's for injection to achieve a final volume of 50 ml.
14 Once diluted, plazomicin may be stored for up to 24 hours at room temperature.
14 After dilution, plazomicin should be infused IV over 30 minutes. 14 According to the prescribing information, plazomicin should not be mixed with other drugs because compatibility has not been established. 14 However, results of a study to determine the physical compatibility of plazomicin during simulated Y-site administration with other drugs showed that plazomicin is compatible with 79 drugs and incompatible with these 13 drugs: albumin, amiodarone, amphotericin B deoxycholate, anidulafungin, calcium chloride, daptomycin, esomeprazole, heparin, levofloxacin, methylprednisolone, micafungin, phenytoin, and propofol. 69 
Place in Therapy
Plazomicin is approved by the FDA for the treatment of adults with cUTIs including pyelonephritis caused by the following susceptible Enterobacteriaceae: E. coli, K. pneumoniae, P. mirabilis, and E. cloacae.
14 Plazomicin should be reserved for use in patients with limited or no alternative treatment options because of limited efficacy and safety data.
14 Although plazomicin has been studied in a small number of patients with BSIs and HABP/VABP caused by CRE, the FDA has issued a complete response letter stating that the clinical trial that evaluated plazomicin for these infections does not provide substantial evidence of effectiveness for these indications primarily because of its small sample size and the inability to conduct robust inferential statistical analyses. 28, 70 Because plazomicin retains activity against ESBLs and AMEs, it has the potential to be used off-label for the treatment of multidrug-resistant gram-negative rods including CRE as monotherapy for cUTIs or in combination with other antibiotics such as meropenem or tigecycline for more serious infections. 62, 71 Plazomicin may have a role in S. aureus infections based on in vitro data, but clinical trials are needed to demonstrate efficacy. Plazomicin has variable activity against P. aeruginosa and no activity against A. baumannii, S. maltophilia, streptococci, enterococci, and anaerobic organisms. 14, 27, 28 As expected from an aminoglycoside antibiotic, plazomicin is associated with nephrotoxicity and ototoxicity.
14 Plazomicin is an aminoglycoside, so it can be used in patients with known hypersensitivity to b-lactam and sulfa antibiotics. At the time of writing this article, no clinical data were available on the use of plazomicin for indications other than cUTIs, BSIs, and HABP/VABP. When deciding on whether to include or exclude plazomicin on the formulary, the institution's antibiogram and patterns of antimicrobial resistance must be considered. In addition, to prevent inappropriate use, institutions should consider developing criteria for use, such as use in patients at high risk for resistant Enterobacteriaceae infections, those at high risk for C. difficile infection, and those with allergies to other antibiotics. 72, 73 Institutions that select plazomicin to be on formulary should have access to susceptibility testing and should develop a TDM plan. Achaogen has collaborated with ThermoFisher to develop a plazomicin assay to measure susceptibility testing that is currently available for research use only. 27, 74, 75 In addition, Achaogen has collaborated with the Mayo Clinic to process plazomicin trough concentrations. To our knowledge, no published studies examining the cost-effectiveness of the use of plazomicin are available. The cost of therapy has yet to be released and is likely to be a limiting factor in its use due to the availability of cheaper alternative antibiotics. However, a new technology addon payment (NTAP) program was granted by the Centers for Medicare and Medicaid Services for plazomicin when administered in the inpatient setting. The NTAP designation will provide hospitals additional reimbursement of up to 50% of the cost of plazomicin for a period of 2-3 years (effective October 1, 2018). 76 
Conclusion
Plazomicin is a novel aminoglycoside antibiotic active against a broad range of Enterobacteriaceae including CRE and those producing ESBLs and AMEs. Plazomicin has variable activity against P. aeruginosa and is inactive against A. baumannii and S. maltophilia. Plazomicin was shown to be noninferior to meropenem for the treatment of adults with cUTIs including pyelonephritis. In addition to the expected nephrotoxicity and ototoxicity, the most 90 PHARMACOTHERAPY Volume 39, Number 1, 2019 common adverse effects associated with plazomicin are diarrhea, hypertension, headache, nausea, vomiting, and hypotension. Plazomicin will be particularly useful in patients at high risk for resistant Enterobacteriaceae infections, those at high risk for C. difficile infection, and in those who are allergic to other antibiotics.
